Lv1
70 积分 2023-05-17 加入
SNMMI/EANM practice guideline vs. ETA Consensus Statement: differences and similarities in approaching differentiated thyroid cancer management-the EANM perspective
10天前
已完结
Initial Evaluation of Therapy Response after Adjuvant Radioiodine Therapy in Patients with Early-Stage Papillary Thyroid Cancer—Does Time Matter?
27天前
已完结
Reflective analysis on the current 131I adjuvant therapy indications in intermediate- and high-risk differentiated thyroid cancer
1个月前
已完结
Clinical Outcome of (131)I Therapy in Differentiated Thyroid Cancer with Preablative Thyroglobulin below 10 ng/ml
1个月前
已关闭
Clinical Outcome of (131)I Therapy in Differentiated Thyroid Cancer with Preablative Thyroglobulin below 10 ng/ml
1个月前
已关闭
Response to Surgery Assessments for Sparing Radioiodine Remnant Ablation in Intermediate-Risk Papillary Thyroid Cancer
1个月前
已完结
rhTSH for initial and follow up treatments with 131I in follicular thyroid cancer with distant metastasis
1个月前
已关闭
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH
1个月前
已关闭
Recurrent well-differentiated thyroid carcinoma
1个月前
已完结
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide
1个月前
已完结
皖公网安备34019202002308
